Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
12 Jun 24
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
13 May 24
8-K
Regulation FD Disclosure
29 Apr 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
14 Mar 24
8-K
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
7 Feb 24
S-8
Registration of securities for employees
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates
14 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
10 Oct 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates
8 Aug 23
8-K
Terns Pharmaceuticals Announces Leadership Transition
3 Aug 23
UPLOAD
Letter from SEC
12 Jul 23
CORRESP
Correspondence with SEC
29 Jun 23
UPLOAD
Letter from SEC
22 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 23
8-K
Entry into a Material Definitive Agreement
15 May 23
S-8
Registration of securities for employees
15 May 23
424B5
Prospectus supplement for primary offering
15 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
10-K
2022 FY
Annual report
27 Mar 23
8-K
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
27 Mar 23
8-K
Regulation FD Disclosure
13 Mar 23
8-K
Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences
2 Mar 23
EFFECT
Notice of effectiveness
13 Feb 23
CORRESP
Correspondence with SEC
8 Feb 23
UPLOAD
Letter from SEC
7 Feb 23
S-3
Shelf registration
1 Feb 23
8-K
Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference
5 Jan 23
8-K
Terns Announces Pricing of $75 Million Public Offering
23 Dec 22
Latest ownership filings
4
Radhika Tripuraneni
14 Jun 24
4
Ann Elizabeth Taylor
14 Jun 24
4
Hongbo Lu
14 Jun 24
4
Jill M. Quigley
14 Jun 24
4
CARL L GORDON
14 Jun 24
4
JEFFREY B KINDLER
14 Jun 24
4
DAVID A FELLOWS
14 Jun 24
SC 13G/A
BlackRock Inc.
7 Jun 24
SC 13G
Soleus Capital Master Fund, L.P.
7 Jun 24
4
Seokho Bryan Yoon
4 Jun 24
4
Mark J. Vignola
4 Jun 24
4
Melita Sun Jung
2 May 24
3
Melita Sun Jung
2 May 24
4
Change in insider ownership
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
3
Emil Kuriakose
19 Mar 24
SC 13G
Point72 Asset Management, L.P.
7 Mar 24
4
Amy L. Burroughs
5 Mar 24
3
Amy L. Burroughs
15 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
Fairmount Funds Management LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
LAV Biosciences Fund V, L.P.
13 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
BlackRock Inc.
31 Jan 24
4
Jill M. Quigley
25 Jan 24
4
Seokho Bryan Yoon
25 Jan 24
4
Mark J. Vignola
25 Jan 24
4
Erin Quirk
25 Jan 24
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
25 Jan 24
4
Seokho Bryan Yoon
4 Dec 23
4
Mark J. Vignola
4 Dec 23
4
Jill M. Quigley
17 Nov 23
SC 13G/A
FMR LLC
13 Oct 23